CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia

  • Authors:
    • Norihiko Tsuchiya
    • Lizhong Wang
    • Yohei Horikawa
    • Takamitsu Inoue
    • Hideaki Kakinuma
    • Shinobu Matsuura
    • Kazunari Sato
    • Osamu Ogawa
    • Tetsuro Kato
    • Tomonori Habuchi
  • View Affiliations

  • Published online on: January 1, 2005     https://doi.org/10.3892/ijo.26.1.225
  • Pages: 225-231
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Insulin-like growth factor-I (IGF-I) plays an important role in prostate growth, hyperplasia, and carcinogenesis. Circulating IGF-I levels may be modulated by a genetic cytosine-adenine (CA) repeat polymorphism in the promoter region of IGF-I. The association of the polymorphism with the risk of prostate cancer and benign prostatic hyperplasia (BPH) was explored in 303 patients with prostate cancer, 219 patients with BPH and 262 controls. The number of CA repeats ranged from 15 to 22 in case and control subjects. The 19-CA-repeat allele (19-allele) was more frequently observed in both the prostate cancer and BPH patients compared with the controls (prostate cancer versus control: P<0.001; BPH versus control: P=0.001). Compared with non-carriers of the 19-allele, men homo-zygous for the 19-allele had a significantly increased risk of prostate cancer [age-adjusted odds ratio (aOR) = 3.36, 95% confidence intervals (CI) = 1.30-8.67, P=0.012] or BPH (aOR = 3.53, 95% CI = 1.32-9.46, P=0.012), and those heterozygous for the 19-allele also had an intermediate increased risk of prostate cancer (aOR = 1.78, 95% CI = 1.25-2.53, P=0.001) or BPH (aOR = 1.66, 95% CI = 1.14-2.43, P=0.009). A gene dosage effect for the aORs was found with an increasing number for the 19-allele (P<0.001 in prostate cancer and P=0.001 in BPH). No significant association was found between the presence of the 19-allele and the tumor stage and grade at the time of diagnosis. In conclusion, the 19-allele of IGF-I appears to increase the risk of prostate cancer and BPH with a gene dosage effect in the Japanese population.

Related Articles

Journal Cover

January 2005
Volume 26 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tsuchiya, N., Wang, L., Horikawa, Y., Inoue, T., Kakinuma, H., Matsuura, S. ... Habuchi, T. (2005). CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. International Journal of Oncology, 26, 225-231. https://doi.org/10.3892/ijo.26.1.225
MLA
Tsuchiya, N., Wang, L., Horikawa, Y., Inoue, T., Kakinuma, H., Matsuura, S., Sato, K., Ogawa, O., Kato, T., Habuchi, T."CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia". International Journal of Oncology 26.1 (2005): 225-231.
Chicago
Tsuchiya, N., Wang, L., Horikawa, Y., Inoue, T., Kakinuma, H., Matsuura, S., Sato, K., Ogawa, O., Kato, T., Habuchi, T."CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia". International Journal of Oncology 26, no. 1 (2005): 225-231. https://doi.org/10.3892/ijo.26.1.225